Navigation Links
Developing a new vaccine using a new technology

The International AIDS Vaccine Initiative (IAVI) together with GlaxoSmithKline Biologicals// (GSK Biologicals) have announced a public-private partnership to develop an AIDS vaccine using a new technology. The human primate adenovirus vector technology was derived from research conducted by scientists at the University of Pennsylvania. The technology is owned by the University and is exclusively licensed to GSK.

According to the agreement, IAVI and GSK will collaborate to advance the development of the technology, which uses non-infectious vaccine vectors to stimulate specific immune responses directed against HIV, the virus that causes AIDS. The vectors are derived from adenoviruses, originally isolated from non-human primates, which have been engineered to be non-infectious and capable of efficiently delivering genes expressing HIV proteins to the immune system. IAVI will play a role in contributing technical expertise and funding and thus form a joint R&D team together with GSK.

Members of the team say that the initial research will focus on designing vaccines to elicit immune responses against variants of HIV that circulate predominantly in Africa and after pre-clinical evaluation, GSK Biologicals and IAVI plan to conduct Phase I clinical trials of the vaccine candidates. The R& D team has also promised that they would wholeheartedly work towards making a successful vaccine very soon and make it available to developing countries at affordable prices.

Both companies say they hope this will be the beginning of a long-term partnership and is a model for how the public and private sectors can work together. The private sector has an immense amount of knowledge, resources and expertise, and they say that an innovative partnership such as this are essential to tackle global health challenges. Hilary Benn, UK Secretary of State for International Development has stressed on the need of an an AIDS vaccine in the fight against disease an d extreme poverty in the developing world, particularly in Africa and also says that such types of collaboration between the public and private sectors is critical for enhancing the research and development of new vaccines against the world’s most devastating infectious diseases.


'"/>




Related medicine news :

1. Risk Of Developing Arthritis
2. Developing HIV fighter
3. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
4. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
5. Men Who at Risk Of Developing Prostate Cancer
6. Identifying The Risks Of Developing Schizophrenia
7. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
8. Cancer Patients At A Greater Risk Of Developing Blood Clots
9. Young Smokers at Increased Risk Of Developing a Heart Attack
10. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
11. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: